This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (1)  • Contact me when this article is cited  Related Content  • Similar articles in this journal

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Thomas makes several erroneous statements in respect to antiphospholipid antibody (APLA) syndromes in his review entitled "Hypercoagulability Syndromes."¹ Since readers may use these recommendations for patient management decisions, we believe that these statements need to be corrected.

1. Thomas states that the incidence of APLA syndrome is 28%. No data exist to support this statement. The actual incidence of the syndrome in patients with venous thromboembolism, as defined by the Sapporo criteria, is not known.² Several studies have looked at the incidence of APLAs in patients with venous thromboembolism, with results ranging from 5.2% to 21%.^3-4 These studies used only a single measurement for APLAs. Since some APLAs are transient and the APLA syndrome is defined by repeatedly positive APLA test results, the incidence of the APLA syndrome is likely lower than 5.2% to 21%.

2. It is not correct that " . . . in 65% of patients [with . . . [Full Text of this Article]